Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an Anti IL17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa

Authors

Lisa Prussick
Brooke Rothstein
Deep Joshipura
Ami Saraiya
Yana Turkowski
Rana Abdat
Abdullah Alomran
Pedro Zancanaro
Courtney Kachuk
Nicole Dumont
Alice B. Gottlieb, New York Medical CollegeFollow
David Rosmarin

DOI

10.1111/bjd.17822

Journal Title

The British Journal of Dermatology

First Page

609

Last Page

611

Document Type

Letter to the Editor

Publication Date

September 2019

Department

Dermatology

Abstract

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease of the apocrine gland-rich intertriginous areas.(1) HS lesions have an elevated Th17 immune response, and it is often challenging to treat patients, with existing therapies having limited efficacy.(2,3) We sought to investigate the role of secukinumab, a human monoclonal antibody that inhibits Interleukin-17A, in HS treatment. This article is protected by copyright. All rights reserved.

Recommended Citation

Prussick, L., Rothstein, B., Joshipura, D., Saraiya, A., Turkowski, Y., Abdat, R., Alomran, A., Zancanaro, P., Kachuk, C., Dumont, N., Gottlieb, A., & Rosmarin, D. (2019). Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an Anti IL17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa. The British Journal of Dermatology, 181 (3), 609-611. https://doi.org/10.1111/bjd.17822